Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426134 | 0.83 | CETP (0.43) | LMNANPC1RAB9A | |
| SCHEMBL28803977 | 0.81 | MTNR1B (0.51) | MTNR1AMTNR1BHSD17B2HSD17B1LMNA | |
| SCHEMBL2117365 | 0.80 | SMN1; SMN2 (0.47) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14861071 | 0.79 | GMPS (0.42) | MTNR1AMTNR1B | |
| SCHEMBL2194318 | 0.79 | NR4A1 (0.45) | MTNR1AMTNR1BHSD17B2HSD17B1NPC1 | |
| SCHEMBL1555330 | 0.78 | ALDH1A1 (0.50) | HSD17B2HSD17B1LMNASMN1; SMN2NLRP3 | |
| SCHEMBL20264517 | 0.78 | HSD17B2 (0.61) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL26907935 | 0.78 | GAA (0.57) | MTNR1AMTNR1BLMNANPC1SMN1; SMN2 | |
| SCHEMBL2447967 | 0.77 | LMNA (0.49) | MTNR1AMTNR1BHSD17B2HSD17B1LMNA | |
| SCHEMBL7379122 | 0.77 | RXRA (0.45) | LMNANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MTNR1A 2295/4885MTNR1B 1316/4885HSD17B2 1474/4885 |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MTNR1A 2295/4885MTNR1B 1316/4885HSD17B2 1474/4885 |
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MTNR1A 2295/4885MTNR1B 1316/4885HSD17B2 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.